current
outbreak
novel
coronaviru
coronaviru
diseas
previous
hubei
provinc
peopl
republ
china
spread
mani
countri
januari
emerg
committe
declar
global
health
emerg
base
grow
case
notif
rate
chines
intern
locat
case
detect
rate
chang
daili
track
almost
real
time
websit
provid
john
hopkin
univers
forum
midst
februari
china
bear
larg
burden
morbid
mortal
wherea
incid
asian
countri
europ
north
america
remain
low
far
coronavirus
envelop
posit
larg
rna
virus
infect
human
also
wide
rang
anim
coronavirus
first
describ
tyrel
byno
cultiv
virus
patient
common
cold
base
morpholog
spheric
virion
core
shell
surfac
project
resembl
solar
corona
term
coronavirus
latin
corona
crown
four
subfamili
name
exist
appar
origin
mammal
particular
bat
origin
pig
bird
genom
size
vari
kb
kb
among
seven
subtyp
coronavirus
infect
human
may
caus
sever
diseas
fatal
wherea
caus
asymptomat
mildli
symptomat
infect
belong
b
lineag
close
relat
viru
major
four
structur
gene
encod
nucleocapsid
protein
n
spike
protein
small
membran
protein
sm
membran
glycoprotein
addit
membran
glycoprotein
occur
ident
level
bat
coronaviru
appar
succeed
make
transit
anim
human
huanan
seafood
market
wuhan
china
howev
endeavour
identifi
potenti
intermedi
host
seem
neglect
wuhan
exact
rout
transmiss
urgent
need
clarifi
initi
clinic
sign
diseas
allow
case
detect
pneumonia
recent
report
also
describ
gastrointestin
symptom
asymptomat
infect
especi
among
young
children
observ
far
suggest
mean
incub
period
five
day
median
incub
period
day
rang
day
proport
individu
infect
remain
asymptomat
throughout
cours
infect
yet
definit
assess
symptomat
patient
clinic
manifest
diseas
usual
start
less
week
consist
fever
cough
nasal
congest
fatigu
sign
upper
respiratori
tract
infect
infect
progress
sever
diseas
dyspnoea
sever
chest
symptom
correspond
pneumonia
approxim
patient
seen
comput
tomographi
admiss
pneumonia
mostli
occur
second
third
week
symptomat
infect
promin
sign
viral
pneumonia
includ
decreas
oxygen
satur
blood
ga
deviat
chang
visibl
chest
imag
techniqu
ground
glass
abnorm
patchi
consolid
alveolar
exud
interlobular
involv
eventu
indic
deterior
lymphopenia
appear
common
inflammatori
marker
protein
proinflammatori
cytokin
elev
recent
investig
confirm
case
demonstr
current
epidem
may
doubl
number
affect
individu
everi
seven
day
patient
spread
infect
individu
averag
estim
outbreak
report
recent
analysi
earli
phase
outbreak
estim
mean
rang
dens
commun
particular
risk
vulner
region
certainli
africa
due
dens
traffic
china
africa
african
countri
suffici
appropri
diagnost
capac
obviou
challeng
exist
handl
outbreak
inde
viru
might
soon
affect
africa
identifi
countri
algeria
angola
cote
ivoir
democrat
republ
congo
ethiopia
ghana
kenya
mauritiu
nigeria
south
africa
tanzania
uganda
zambia
either
maintain
direct
link
china
high
volum
travel
china
recent
studi
indic
patient
year
age
higher
risk
children
might
less
like
becom
infect
may
show
milder
symptom
even
asymptomat
infect
februari
case
fatal
rate
infect
approxim
februari
pm
cet
epidem
outbreak
sinc
like
virus
infect
lung
alveolar
epitheli
cell
use
endocytosi
via
enzym
ii
entri
receptor
artifici
intellig
predict
drug
associ
protein
kinas
disrupt
protein
may
inhibit
viral
entri
target
cell
baricitinib
use
treatment
rheumatoid
arthriti
janu
kinas
inhibitor
suggest
control
viral
replic
moreov
one
vitro
clinic
studi
indic
remdesivir
adenosin
analogu
act
viral
protein
inhibitor
improv
condit
one
patient
chloroquin
increas
endosom
ph
requir
fusion
potenti
block
viral
infect
shown
affect
activ
protein
kinas
mapk
involv
replic
combin
antiretrovir
drug
lopinavir
ritonavir
significantli
improv
clinic
condit
patient
might
option
infect
possibl
includ
leronlimab
humanis
monoclon
antibodi
antagonist
galidesivir
nucleosid
rna
polymeras
inhibitor
shown
surviv
benefit
sever
deadli
viru
infect
consid
potenti
treatment
candid
repurpos
avail
drug
immedi
use
treatment
infect
could
improv
current
avail
clinic
manag
clinic
trial
present
regist
clinicaltrialsgov
focu
efficaci
remdesivir
immunoglobulin
arbidol
hydrochlorid
combin
interferon
atomis
ritonavir
plu
oseltamivir
lopinavir
plu
ritonavir
mesenchym
stem
cell
treatment
darunavir
plu
cobicistat
hydroxychloroquin
methylprednisolon
wash
microbiota
transplant
given
fragil
health
system
african
countri
new
diseas
outbreak
current
epidem
potenti
paralys
health
system
expens
primari
healthcar
requir
impact
ebola
epidem
economi
healthcar
structur
still
felt
five
year
later
countri
affect
effect
outbreak
respons
prepared
emerg
magnitud
challeng
across
african
countri
situat
partli
mitig
support
exist
region
african
health
structur
